Neuromuscular junction

14 September 2022

PARALLEL 1

• 14-PM-Parallel-1 • 16:30 > 18:00 • Neuromuscular junction • Apollon Auditorium

16:30 • S13L1 • New treatments for autoimmune myasthenia gravis > E. Emilien DELMONT (Marseille, France) 17:00 • S13L2 • Use of human pluripotent stem cells for Neuromuscular Disorders > C. Cecile MARTINAT (Evry, France) 17:30 • S13L3 • Targeting the neuromuscular junction (NMJ) to treat congenital myasthenic syndromes and inherited motor neuropathies with NMJ dysfunction > S. Sally SPENDIFF (Ottawa, Canada)